ASH20
Neha Korde, MD ...
Parameswaran Hari, MD, speaks about myeloma research presented at the virtual 2020 ASH Annual Meeting.
Findings presented at the ASH 2020 Annual Meeting & Exposition found that almost half of patients with multiple myeloma (MM) ...
Advertisement
A study presented at the ASH Annual Meeting found that among 6 landmark multiple myeloma clinical trials, the ineligibility ...
Iberdomide, an oral potent novel cereblon E3 ligase modulator (CELMoD), demonstrated an acceptable toxicity profile and ...
DARA is an anti-CD38 antibody approved for the treatment of RRMM.
CT053 is a second-generation CAR T that incorporates a fully human BCMA-specific single-chain fragment variant.
Results from the PRIME study found that P-BCMA-101, an autologous CAR T-cell therapy, was effective and safe for patients ...
Patients with high-risk myeloma may not be appropriately recognized as having high-risk disease at diagnosis, according to a ...
Insurance status was found to be significantly associated with survival for patients with multiple myeloma, according to ...
Individuals with MM are at increased risk for developing VTE.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.